ArticleJournal of medical biochemistry2026
The levels of interleukin-6, serum calprotectin, and hypersensitive C-reactive protein in patients with Crohn's disease-related mucosal damage.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the ability of calprotectin, hypersensitive C-reactive protein, and interleukin-6 to detect digestive tract mucosal injury in patients with Crohn's disease (CD). Methods: Fifty-two patients diagnosed with CD were selected. Faecal samples from the patients were collected to detect calprotectin (ELISA), and serum samples were collected to detect hs-CRP (immunoturbidimetry) and IL-6 (chemiluminescence). All patients with CD underwent colonoscopy or capsule endoscopy, according to the modified endoscopic severity index of CD (SES-CD). Comparisons of the differences in calprotectin, hs-CRP and IL-6 levels were made between the two groups, and receiver operating characteristic (ROC) curves were drawn to analyse the diagnostic efficacy (AUC) of each index and combined detection for mucosal injury. Results: In the Mucosal injury group, the calprotectin and hs-CRP levels were significantly greater than those in the Mucosal healing group. According to the ROC analysis, calprotectin had the highest AUC (0.93, 95% CI: 0.88-0.98), sensitivity (88.5%) and specificity (89.2%) when the critical value was greater than 250 mg/g. The AUC of the three indicators' combined detection (logistic regression model) rose to 0.96, which was noticeably superior to that of a single indicator (P< 0.05). Conclusions: Interleukin-6, serum calprotectin, and hypersensitive C-reactive protein levels are significantly correlated with the degree of mucosal injury in patients with CD. Among them, calprotectin has the best diagnostic value. The combined detection of these three factors can significantly improve the recognition of mucosal injury in the active stage of CD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.